Canine Cognitive Dysfunction Syndrome

Maggie O’Brian, DVM, MS, DACVB, Southeast Animal Behavior & Training, Charlotte, North Carolina

ArticleNovember 20269 min readPeer Reviewed
Featured Image

Overview

Canine cognitive dysfunction syndrome (CCDS) is a chronic, progressive, age-related neurodegenerative disease process in dogs that results in behavioral changes secondary to brain pathology.1 Signs of cognitive dysfunction include apparent working memory loss, changes in sociability, and anxiety. Diagnosis is typically presumptive based on presence of behavioral changes and exclusion and/or treatment of potential comorbidities. Definitive diagnosis can only be determined postmortem. Treatment includes medication, supplements, behavioral modification, and environmental adjustments.

Epidemiology

Incidence/Prevalence

  • CCDS occurs in 14.2% to 73% of dogs, depending on the study and age group; prevalence increases with age.2-4

Signalment

Breed Predisposition

  • None

Age

  • Prevalence increases with age; screening typically starts at 8 years of age.

Sex

  • Some studies suggest female and neutered dogs are overrepresented, while others found no sex predisposition.3,5,6

Genetic Implications

  • A genetic component to CCDS has not been confirmed; however, other disease processes associated with cognitive impairment (eg, Alzheimer’s disease in humans) have genetic risk factors. A genetic component is thus likely in dogs as well, given the translational nature of the diseases.1,7

Causes & Risk Factors

  • Age is the most significant and consistent risk factor.3,4,8

  • Idiopathic epilepsy9

  • Hypercortisolism (Cushing’s disease)10

Pathophysiology

CCDS is caused by changes to the brain as a result of aging that can include buildup of amyloid beta plaques, as well as oxidative and vascular damage to the neurons, resulting in cognitive impairment.11 Pathologic findings may suggest canine cognitive decline but can only be fully assessed postmortem. Macroscopic changes include cerebral atrophy and ventricular enlargement.12 Progressive brain changes result in behavioral changes, including increased anxiety, apparent working memory loss, disorientation, and changes in sociability.

History

Dogs are typically presented with behavioral changes often associated with cognitive decline. Pet owners often seek help with the most disruptive behavioral changes (ie, sleeplessness, house soiling, vocalization/pacing in the evening). Subtle signs of cognitive decline may be more noticeable in patients with a history of extensive training.

Clinical Presentation

  • The acronym DISHAA is used to organize the clinical signs of CCDS: disorientation, impaired social interactions, sleep disturbances, house soiling/learning/memory deficits, activity level changes, and increased anxiety and fear.11Dogs with CCDS or increased risk for developing CCDS may also have increased risk for aggression toward familiar humans and animals.13

    • Disorientation

      • Staring at walls, getting stuck behind furniture, walking into doors/walls

    • Impaired social interactions

      • Increased fear and irritability, decreased interest in being touched or interacting

    • Sleep/wake cycle changes

      • Reduced ability to sleep through the night, increased sleeping during the day

    • House soiling/changes in memory

      • Loss of learned tricks, difficulty with learning/training

    • Activity level changes

      • Reduced play with toys, humans, other animals; increased pacing/wandering

    • Anxiety and fear increased

      • Increased separation anxiety, more fearful of sounds/visual changes, fear of novel locations

Differential Diagnoses

  • Clinical signs of CCDS significantly overlap with other disease processes. Comorbidities should be ruled out via thorough physical examination (including orthopedic and neurologic examination), complete initial clinicopathologic screening (ie, CBC, serum chemistry profile, urinalysis, thyroid panel), and follow-up laboratory testing or imaging as needed based on initial findings.

    • Physical discomfort/pain

      • Pain can lead to increased anxiety and aggression. Dogs with CCDS may have a quicker startle response, reduced ability to settle, and hypervigilance, among other signs.

      • Increased difficulty resting comfortably may result in pacing in the evening, difficulty sleeping through the night, and/or reduced activity during the day.

      • Reduced willingness to travel to typical soiling areas can result in house soiling incidents. For example, physical discomfort may result in a dog urinating or defecating inside the home instead of walking down steps or going outside.

      • Pain can result in less tolerance or seeking of physical interaction with humans. Alternatively, pain may lead some dogs to seek more physical interaction and comfort.

    • House soiling should prompt investigation for diseases that result in polyuria and polydipsia (eg, chronic kidney disease, diabetes mellitus, hypercortisolism).

    • Patients with Cushing’s disease can be presented with pacing, anxiety, aggression, and house soiling. This condition can also directly affect cognitive function.

    • Structural, infectious, or inflammatory CNS diseases can alter memory, learning, and personality.

    • Sensory changes can lead to disorientation, changes in sociability due to fear or confusion, increased anxiety, and other behavioral changes.

Diagnostics & Diagnostic Findings

  • Patients should be routinely screened beginning at 7 years of age and every 6 months thereafter to monitor for presence and progression of behavioral signs associated with CCDS.

  • Owner-completed surveys assessing clinical signs for CCDS include the Canine Cognitive Dysfunction Rating (CCDR) scale and the Canine Dementia Scale (CADES).2,14 The DISHAA acronym can also offer subjective insights into prevalence and severity of behavioral changes.

  • MRI can be used to assess for cerebral atrophy and ventricular enlargement suggestive of CCDS, but this option is not routinely pursued by owners.15

Definitive Diagnosis

  • Although owner surveys are an important initial assessment, diagnosis based on surveys is not definitive, and differentials should be ruled out. Several screening tools are available.2,11,14

  • MRI findings consistent with CCDS are brain atrophy and cerebral microbleeds.16,17

  • CSF samples should be normal and can be used to rule out other diagnoses.

Relevant Laboratory Tests

  • Laboratory testing can help rule out differentials.

  • One study suggested patients with mild CCDS have elevated liver enzyme activities (ie, AST, ALT) and decreased sodium and chloride levels.18

Postmortem Findings

  • Amyloid beta plaques and phosphorylated tau are markers of Alzheimer’s disease in humans and are associated with aging canine brains, but the direct association with cognitive decline is not as clear. Dogs with CCDS typically demonstrate cortical atrophy along with ventricular enlargement, as well as hippocampal neuron loss. Evidence of myelin reduction, neuroinflammation, and oxidative damage can also be seen.11

Treatment

Inpatient/Outpatient

  • Outpatient

Medical

  • Long-lasting daily medications can help treat cognitive decline or anxiety secondary to cognitive decline, and fast-acting medications can be administered alone or in conjunction with a long-lasting medication to treat anxiety (eg, separation concerns, sleeping difficulties) secondary to cognitive decline as needed.

    • Long-lasting medications

      • Selegiline is a monoamine-oxidase-B inhibitor (ie, MAO-B) that increases the level of circulating monoamines (eg, serotonin; norepinephrine; most notably, dopamine) to improve memory and cognition. Selegiline may also reduce free radicals. In one study, selegiline resulted in improvement in 77% of dogs.19 Full effects can take 4 to 6 weeks. Drug interaction monitoring is vital, as selegiline can adversely interact with numerous medications, especially those that may also increase monoamines (eg, selective serotonin reuptake inhibitors [SSRIs], tricyclic antidepressants [TCAs], trazodone, tramadol, opioids, amitraz, amphetamines, alpha-2-agonists). Selegiline is not safe for use with daily antianxiety serotonergic medications (eg, SSRIs, TCAs), and long washout periods are needed if switching treatment between these drugs.

      • Alternatively, a long-lasting daily antianxiety medication (eg, SSRIs, TCAs) may be chosen for patients in which anxiety is the primary sign of CCDS. SSRIs should be prioritized over TCAs due to a lower adverse effect profile in geriatric patients. Full effects can also take 4 to 6 weeks.

    • Fast-acting medications

      • A common concern for dogs with cognitive decline is a change in the sleep–wake cycle. Medication can be administered at night to help improve sleep quality.

      • Gabapentin, pregabalin, clonidine, benzodiazepines, and trazodone can help dogs with increased situational anxiety (eg, separation, travel) or be considered for daily routine use. For daily routine use, nonsedating doses should be used to improve anxiety, typically in addition to long-lasting medication.

Supplements That Support Cognitive Health

  • No studies directly compare supplemental support options for cognitive decline. Omega-3 fatty acids show the most promise for cognitive support.20 Dietary management, including a therapeutic cognitive/mobility diet, is convenient and generally safe, offering a combination of supportive supplements in one option.21,22

    • Omega-3 fatty acids may improve learning and help prevent memory decline.21-24

    • One supplement containing phosphatidylserine, ginkgo biloba extract, resveratrol (grape extract), vitamin E (d-alpha-tocopherol), and vitamin B6 (pyridoxine) is considered safe and can be recommended routinely for dogs ≥8 years of age.4

    • Two studies have shown improvement in patients administered supplements for cognitive decline compared with placebo4,25; proactive, early implementation may help delay onset of cognitive decline.

    • S-adenosylmethionine may improve executive function, helps alleviate clinical signs of CCDS, and has serotonergic effects. Caution should be used when administered in combination with other serotonergic medications, particularly selegiline.26,27

Activity

  • Enrichment tools and activities that encourage sniffing (eg, food dispensing toys, slow walks) can be beneficial. Food dispensing toys provide rewarding mental engagement, and sniff walks allow for exploration and sensory stimulation.

  • Regular exercise is shown to be protective for development of CCDS and should be encouraged lifelong, including after a diagnosis of CCDS, when possible.28

  • Regular positive-reinforcement–based training can encourage learning new tricks for mental stimulation.

    • Offering senior dog training classes at the clinic may help educate owners while providing regular enrichment and training opportunities for patients.29

  • Sources of physical discomfort and pain should be addressed.

Monitoring & Follow-Up

  • Annual screening via an owner survey should start when dogs reach 7 years of age, and the survey should be completed every 6 months if there are concerns. If there are no concerns, surveys can be completed annually until dogs reach 10 years of age. Dogs ≥10 years of age should be screened every 6 months.11

Complications

Dogs with CCDS may exhibit anxiety, which can be situational or generalized and should be assessed and treated accordingly.

Prognosis

CCDS is a progressive disease, but interventions can delay or slow clinical signs and help maintain adequate quality of life. Owners should use quality of life assessments throughout the disease process. Caregiver burden should be considered, as this condition is often very distressing for owners. Many senior dogs with CCDS succumb to an unrelated comorbidity. Euthanasia may be elected when cognitive decline sufficiently impacts patient or owner quality of life.

Prevention & Owner Education

  • Physical activity should be provided, ideally early in life, as a protective benefit. In one study of >11,000 dogs, those with greater physical exercise demonstrated fewer signs of cognitive decline and slower progression of cognitive decline.28

  • Lifelong learning and training with appropriate training methods (eg, no electric collars, prong collars, choke collars) can improve cognitive function.28

  • Early intervention can be beneficial, with owners beginning surveys when the dog is 7 years of age and discussing behavioral changes with the clinician.

  • Early treatment for the presenting complaint is more likely to be successful.

  • Daily routines should be predictable and meet enrichment needs (eg, social interactions, physical activity, training, rest).

  • Rearranging furniture in the home should be avoided, as dogs with CCDS can become disoriented.

    • Avoiding changes in furniture arrangement is especially important for dogs with vision impairment.

  • Giving attention for demanding behaviors should be avoided. Dogs should be encouraged to settle on a bed or mat to relax and wait patiently for social interactions.

  • White noise machines, blackout curtains, and/or a night light (patient dependent) can be offered for sleeplessness. Medication should be considered to facilitate sleep and address comorbid pain.

  • For house soiling, owners should be encouraged to revisit house training (eg, providing rewards for going outside; blocking access to accident areas; avoiding punishment, which can increase anxiety and worsen the problem).